Natriumklorid-Glucos Baxter Viaflo 4,5 mg/ml + 25 mg/ml infusionsvæske, opløsning Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

natriumklorid-glucos baxter viaflo 4,5 mg/ml + 25 mg/ml infusionsvæske, opløsning

baxter a/s - glucosemonohydrat, natriumchlorid - infusionsvæske, opløsning - 4,5 mg/ml + 25 mg/ml

Tepadina Evropská unie - dánština - EMA (European Medicines Agency)

tepadina

adienne s.r.l. s.u. - thiotepa - hematopoietisk stamcelletransplantation - antineoplastiske midler - i kombination med andre kemoterapeutiske lægemidler:med eller uden total body bestråling (tbi) som konditionering behandling forud for allogen eller autolog hæmatopoietisk stamcelletransplantation (hpct) hæmatologiske sygdomme hos voksne og pædiatriske patienter, når høj-dosis kemoterapi med hpct support er passende til behandling af solide tumorer hos voksne og pædiatriske patienter. det foreslås, at tepadina skal ordineres af læger med erfaring i plejende behandling forud for hæmatopoietisk stamcelletransplantation.

Vitrakvi Evropská unie - dánština - EMA (European Medicines Agency)

vitrakvi

bayer ag - larotrectinib sulfat - abdominal neoplasmer - antineoplastiske midler - vitrakvi som monoterapi er indiceret til behandling af voksne og pædiatriske patienter med solide tumorer, hvor der vises en neurotrophic receptor tyrosin kinase (ntrk) gen fusion,der har en sygdom, der er lokalt avanceret, metastatisk eller hvor kirurgisk resektion er sandsynligvis resultere i alvorlig sygelighed, andwho har ingen tilfredsstillende behandling valg.

Rozlytrek Evropská unie - dánština - EMA (European Medicines Agency)

rozlytrek

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Thiotepa Riemser Evropská unie - dánština - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiske midler - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Pedmarqsi Evropská unie - dánština - EMA (European Medicines Agency)

pedmarqsi

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - alle andre terapeutiske produkter - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

balance 1,5 % glucose, 1,25 mmol/l calcium peritonealdialysevæske Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

balance 1,5 % glucose, 1,25 mmol/l calcium peritonealdialysevæske

fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natrium(s)-lactat opløsning, natriumchlorid - peritonealdialysevæske

balance 1,5 % glucose, 1,75 mmol/l calcium peritonealdialysevæske Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

balance 1,5 % glucose, 1,75 mmol/l calcium peritonealdialysevæske

fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natriumacetat, natriumchlorid, natriumlactat opløsning - peritonealdialysevæske

balance 2,3 % glucose, 1,25 mmol/l calcium peritonealdialysevæske Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

balance 2,3 % glucose, 1,25 mmol/l calcium peritonealdialysevæske

fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natrium(s)-lactat opløsning, natriumchlorid - peritonealdialysevæske

balance 2,3 % glucose, 1,75 mmol/l calcium peritonealdialysevæske Dánsko - dánština - Lægemiddelstyrelsen (Danish Medicines Agency)

balance 2,3 % glucose, 1,75 mmol/l calcium peritonealdialysevæske

fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natriumacetat, natriumchlorid, natriumlactat opløsning - peritonealdialysevæske